Kalorama Forecasts $2.3 Billion HbA1c Market by 2029, Driven by POC Growth, Emerging Markets, and Digital Innovation

ARLINGTON, Va., June 4, 2025 /PRNewswire/ — Kalorama Information, a leading publisher of healthcare market research, has released The World Market for HbA1c Testing: Trends, Technologies, and Growth Opportunities, 2025, in conjunction with a related webinar held in April. This comprehensive report delivers critical insights for diagnostic developers, healthcare providers, investors, and strategic planners navigating the rapidly expanding global HbA1c testing market.

In 2024, the global HbA1c in vitro diagnostics (IVD) market generated $1.7 billion and is projected to reach $2.3 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.7%. The report underscores the growing role of HbA1c testing in diabetes screening, monitoring, and personalized care—particularly as point-of-care (POC) adoption accelerates to meet demand for fast, decentralized diagnostics.

“Laboratory-based testing has long been the gold standard for HbA1c,” said Daniel Granderson, Senior Editor at Kalorama Information. “But with advancing technology and rising demand, we’re seeing a significant shift toward POC testing. These platforms have been a major driver of diagnostics market growth over the past decade.”

Key Findings:

  • North America and Europe accounted for over 73% of 2024 revenues, but Asia-Pacific and Latin America are gaining momentum due to aging populations, rising diabetes prevalence, and expanding healthcare systems.
  • Lab-based HbA1c testing remains dominant, but POC platforms are growing faster due to convenience and innovation.
  • Abbott leads the market with a 17% share, followed by Roche (11%) and Bio-Rad. The top five HbA1c competitors combine to account for 45% of the overall market.
  • Emerging technologies—nanotech, mobile-connected assays, AI, and deep learning—are enabling real-time, home-based monitoring and predictive care.

Why This Report Matters Now:

As global diabetes rates climb and healthcare systems emphasize chronic disease management and cost control, HbA1c testing is central to improving outcomes. The integration of digital tools, biosensor innovation, and government screening programs is reshaping how and where testing is done. This report gives stakeholders a clear view of:

  • Where growth is happening (geographically and technologically)
  • How to enter or expand in the market
  • Which products and competitors are gaining share
  • What barriers exist in reimbursement, pricing, and procurement
  • How to prioritize investments and R&D pipelines

Who Should Read This Report:

  • Diagnostic & Medical Device Companies
  • Strategic Planners & Business Development Leaders
  • Investors and Venture Capital Firms
  • Healthcare Providers and Laboratory Networks
  • Policy Makers and Reimbursement Authorities

Whether you’re building a product roadmap, evaluating acquisition targets, or justifying a strategic pivot, this report provides the data, competitive intelligence, and trend forecasting you need to move forward with confidence.

Access the Report & Webinar

For more information or to request a custom consultation, contact:
Sheri Davie
Kalorama Information Sales Team
sheri.davie@scienceandmedicinegroup.com

For all other inquiries contact:
Alisa Alvich
Marketing Director
alisa.alvich@scienceandmedicinegroup.com 

About Kalorama Information

For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kalorama-forecasts-2-3-billion-hba1c-market-by-2029–driven-by-poc-growth-emerging-markets-and-digital-innovation-302464732.html

SOURCE Kalorama Information

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

2 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

2 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago